Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Webcast Interview with CEO

19 Jul 2010 07:00

RNS Number : 5036P
ABCAM Plc
19 July 2010
 



For immediate release

19 July 2010

 

 

RNS REACH

 

ABCAM PLC

("Abcam" or "the Company")

 

Webcast interview with Jonathan Milner, CEO

 

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce that a webcast interview with Jonathan Milner, the Company's Chief Executive Officer, is ready to view at the London Stock Exchange website:

 

www.londonstockexchange.com/growing-company-interviews

 

In the interview, Dr Milner discusses the dynamics of the antibody marketplace and gives an insight into Abcam's history and operations, highlighting the importance of the internet to the Company's business model.

 

The interview marks the beginning of a series of webcasts hosted by the London Stock Exchange entitled Growing Company Interviews. The interviews are designed to give investors a better understanding of selected companies quoted on the London market.

 

 

For further information please contact:

 

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

 

 

Notes for editors

 

About Abcam plc

 

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies, from over 250 suppliers. Abcam employs 270 staff in its four operating companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZQLFFBDFEBBV
Date   Source Headline
16th Sep 20198:02 amRNSDirector/PDMR Shareholding
12th Sep 20197:00 amRNSNotice of Capital Markets Event
11th Sep 201910:33 amRNSDirector/PDMR Shareholding
11th Sep 201910:11 amRNSReplacement: Director/PDMR Shareholding
11th Sep 20197:00 amRNSDirector/PDMR Shareholding
9th Sep 20197:00 amRNSFull year results for 12 months ended 30 June 2019
2nd Sep 20193:14 pmRNSTotal Voting Rights
1st Aug 201912:10 pmRNSTotal Voting Rights
22nd Jul 20197:01 amRNSDirectorate Change
22nd Jul 20197:00 amRNSFull Year Trading Update
16th Jul 20197:00 amRNSAcquisition of Cell Lines and Lysates Portfolio
1st Jul 20199:38 amRNSTotal Voting Rights
3rd Jun 201910:45 amRNSTotal Voting Rights
2nd May 201912:53 pmRNSTotal Voting Rights
1st May 20197:00 amRNSAppointment of Joint Broker
2nd Apr 20191:13 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSCompany Secretary Change
12th Mar 20197:00 amRNSHolding(s) in Company
8th Mar 20198:57 amRNSHolding(s) in Company
4th Mar 20197:00 amRNSInterim results for six months ended 31 Dec 2018
1st Mar 201910:29 amRNSTotal Voting Rights
25th Feb 20195:39 pmRNSChange of Registered Office
18th Feb 20191:01 pmRNSBlock listing Interim Review
5th Feb 201911:34 amRNSTotal Voting Rights
28th Jan 20197:00 amRNSAcquisition of Calico Biolabs
8th Jan 20197:00 amRNSHalf Year Trading Update
3rd Jan 20191:45 pmRNSTotal Voting Rights
3rd Jan 20197:00 amRNSAbcam to present at J.P. Morgan Conference
13th Dec 201810:06 amRNSDirectorate Change
6th Dec 20181:06 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:02 pmRNSDirector/PDMR Shareholding
3rd Dec 201812:21 pmRNSTotal Voting Rights
12th Nov 20181:59 pmRNSDirector/PDMR Shareholding
8th Nov 20189:32 amRNSDirector/PDMR Shareholding
6th Nov 20185:47 pmRNSResult of AGM
2nd Nov 20188:51 amRNSTotal Voting Rights
1st Nov 20181:22 pmRNSHolding(s) in Company
29th Oct 20188:57 amRNSDirector/PDMR Shareholding
10th Oct 201810:46 amRNSHolding(s) in Company
9th Oct 20188:59 amRNSDirector/PDMR Shareholding
2nd Oct 201812:54 pmRNSHolding(s) in Company
2nd Oct 201812:51 pmRNSDirector/PDMR Shareholding
1st Oct 20185:41 pmRNSTotal Voting Rights
28th Sep 201810:11 amRNSDirector/PDMR Shareholding
24th Sep 20182:42 pmRNSHolding(s) in Company
21st Sep 201812:56 pmRNSAnnual Financial Report
14th Sep 20189:46 amRNSDirector/PDMR Shareholding
13th Sep 20181:34 pmRNSDirector/PDMR Shareholding
13th Sep 20181:33 pmRNSDirector/PDMR Shareholding
11th Sep 201810:30 amRNSDividend Payment Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.